← All trials
NCT05919407
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 22, 2023
- Primary completion
- Sep 22, 2024
- Completion date
- Sep 22, 2024
- First posted
- Jun 26, 2023
- Last posted
- Jun 26, 2023
- Enrollment
- 24
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Leiden UniversityLead sponsor
- Leiden UniversityReponsible party - principal investigator
- NMD Pharma A/SCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.